Q2 2026 Eris Lifesciences Ltd Earnings Call Transcript
Key Points
- Eris Lifesciences Ltd (NSE:ERIS) reported a 10% year-on-year revenue growth in Q2, outperforming the market growth of 7.7%.
- The company achieved an 11% growth in EBITDA for Q2 and a 13% growth for H1, with margin expansion across the board.
- Eris Lifesciences Ltd (NSE:ERIS) is expanding its collaboration with Biocon, adding Aspart to the partnership, which was recently approved by the US FDA.
- The company has a strong pipeline in the GLP market, with expectations of exponential growth once cheaper generics become available.
- Eris Lifesciences Ltd (NSE:ERIS) has a robust international business strategy, with a significant increase in the EU CDMO order book from INR100 crores to INR700-800 crores, indicating strong future revenue potential.
- The company faced a delay in the approval of gSaxenda, leading to the cancellation of the product.
- There was a delay in implementing price increases in H1, which impacted revenue growth.
- Eris Lifesciences Ltd (NSE:ERIS) experienced an EBITDA hit of INR5 crores due to generics.
- The company has a high net debt of INR1,278 crores, although it has been reduced from previous levels.
- There is a delay in the insulin cartridge capacity expansion at Bhopal, impacting the company's ability to capture market opportunities promptly.
Welcome to the Q2 and H1 FY26 earnings conference call of Eris Lifesciences Limited. Today, we have with us on the call Mr. Amit Bakshi, Chairman and Managing Director; Mr. V. Krishnakumar, Chief Operating Officer and Executive Director; Mr. Sachin Shah, Chief Financial Officer; and Mr. Kruti Raval, VP, M&A and Investor Relations. (Operator Instructions)
Please note, this call is being recorded. I would now like to hand over the conference to Mr. Krishnakumar, Chief Operating Officer and Executive Director of the company. Thank you, and over to you, sir.
Good afternoon, everybody. Welcome to our quarter two investor presentation. We've structured it in three parts. We'll first talk about the Domestic Branded Formulations business. So business highlights for the quarter.
We saw revenue growth of 10% year on year, which is a 30% over IPM growth of 7.7%, H1 growth of 11%, which is a 42% over IPM growth. A couple of key messages and delivering 50%
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
